Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
Ad5Adenovirus serotype 5
AEAdverse event
AHFSAmerican Hospital Formulary Service
ASPAverage sales price
BCBladder cancer
BCGBacillus Calmette-Guérin
BCG-URBCG-unresponsive
BIABudget impact analysis
BLABiologics license application
BSL-2Biosafety level 2
BSTBladder-sparing therapy
CFSCystectomy-free survival
CIConfidence interval
CISCarcinoma in situ
CMSCenters for Medicare and Medicaid Services
COSTComprehensive Score for Financial Toxicity
CPTCurrent Procedural Terminology
CRComplete response
CRRComplete response rate
CSSCancer-specific survival
CTComputed tomography
CTCAECommon Terminology Criteria for Adverse Events
CTUComputed tomography urography
DDMn-dodecyl-β-D-maltoside
DFSDisease-free survival
DORDuration of response
EAUEuropean Association of Urology
ECOGEastern Cooperative Oncology Group
EFSEvent-free survival
EORTCEuropean Organisation for Research and Treatment of Cancer
FDAU.S. Food and Drug Administration
FTFinancial toxicity
GAGGlycosaminoglycan
GM-CSFGranulocyte-macrophage colony-stimulating factor
HCPCSHealthcare Common Procedure Coding System
HGHigh grade
HG-EFSHigh-grade event-free survival
HG-RFSHigh-grade recurrence-free survival
HGUCHigh-grade urothelial carcinoma
HRHazard ratio
ICERInstitute for Clinical and Economic Review
IL-15Interleukin-15
INNInternational nonproprietary name
IQRInterquartile range
ITTIntention to treat
IVEIntravesical
MedDRAMedical Dictionary for Regulatory Activities
MFSMetastasis-free survival
MIBCMuscle-invasive bladder cancer
MMCMitomycin C
MRDMinimal residual disease
MRIMagnetic resonance imaging
MRUMagnetic resonance urography
NAINogapendekin alfa inbakicept
NMIBCNon-muscle-invasive bladder cancer
OSOverall survival
PD-L1Programmed death-ligand 1
PDQPhysician Data Query
PFSProgression-free survival
PMPMPer member per month
QALYQuality-adjusted life year
QoLQuality of life
RCRadical cystectomy
RCTRandomized controlled trial
RFSRecurrence-free survival
RVURelative value unit
SAESerious adverse event
SDStandard deviation
SEERSurveillance, Epidemiology, and End Results
SUOSociety of Urologic Oncology
TRAETreatment-related adverse event
TURBTTransurethral resection of bladder tumor
UCUrothelial carcinoma
USDU.S. dollars
utDNAUrinary tumor DNA
VPViral particles
WACWholesale acquisition cost
WHOWorld Health Organization
wRRWeighted risk ratio
WTPWillingness to pay